Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics

Area of Science:

• Biotechnology
• Vaccinology
• Drug Delivery Systems

Background:

• The COVID-19 pandemic spurred rapid development of vaccines against SARS-CoV-2.
• Messenger RNA (mRNA) vaccines demonstrated high efficacy and rapid deployment capabilities.
• Decades of research in mRNA and delivery technologies underpinned vaccine development.

Purpose of the Study:

• To review the development and significance of lipid nanoparticle (LNP) delivery systems for mRNA therapeutics.
• To honor Dr. Katalin Kariko's foundational contributions to mRNA technology.
• To highlight the potential of mRNA-LNP technology for treating genetic diseases.

Main Methods:

• Review of scientific literature on mRNA and LNP technologies.
• Analysis of historical advancements in therapeutic RNA and nanoparticle delivery.
• Examination of the translation of LNP technology from siRNA to mRNA therapeutics.

Main Results:

• mRNA-based vaccines, enabled by LNP carriers, were successfully developed for COVID-19.
• The development of LNP systems benefited from prior work on siRNA delivery, exemplified by ONPATTRO®.
• Foundational mRNA research by Dr. Kariko and colleagues was crucial for therapeutic applications.

Conclusions:

• Lipid nanoparticle (LNP) delivery systems were essential for realizing the potential of mRNA therapeutics.
• The success of mRNA-LNP vaccines against COVID-19 validates the platform for future applications.
• mRNA-LNP technology represents a new pharmaceutical option for treating genetic diseases.